Affidea has inked a deal to offer artificial intelligence (AI) developer Incepto's platform for use by its radiologists in 14 centers in Portugal in their daily clinical activity.
The Incepto platform now offers Affidea's doctors access to a portfolio of AI products that are integrated with Affidea's PACS/RIS infrastructure. Through a single platform, Affidea's radiologists will be able to access and use AI software focused on oncology, neurology, and breast specialties without changing any equipment or without having to integrate each AI software product separately, Affidea said.
After this first deployment in Portugal, Incepto and Affidea plan to roll out the offering across other Affidea countries in Europe.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
